CM Plus Singapore Pte. Ltd. and CM Plus Corporation (collectively, “CM Plus”) are pleased to announce the signing of a Memorandum of Understanding (MOU) with MetaTech AP Inc. (“MetaTech AP”, 三顧股份有限公司), a Taiwanese biotechnology company, and its subsidiary, Locus Cell Co., Ltd. (“Locus Cell”, 樂迦再生科技股份有限公司).  The MOU establishes a framework for cooperation in the business areas of biologics, regenerative medicine, cell and gene therapy, and AI/DX, covering both Taiwan and international markets, including Japan.

The MOU signing ceremony was held in the presence of Mr. Tsai Ming-Yaw, Deputy Representative of the Taipei Economic and Cultural Representative Office in Japan (Taiwan Representative Office).

The Signing Ceremony (From left: Mr. Jiunn-Rong Chiou, Chairman of Locus Cell; Mr. Tsunehiro Togashi, Group CEO of CM Plus Singapore; Mr. Alex Chen, Vice Chairman of MetaTech AP; Mr. Satoshi Sueko, President of CM Plus Corporation; Mr. Tsai Ming-Yaw, Deputy Representative of Taiwan Representative Office)

 

New Momentum for Taiwan’s Biotech Industry

In recent years, advanced modalities such as biopharmaceuticals and regenerative medicine products have been driving high growth in the pharmaceutical industry.  Within this international supply chain, Taiwan is rapidly increasing its presence as a new hub for regenerative medicine in the Asia-Pacific region.  While Taiwan has traditionally been recognized for its Contract Manufacturing (CMO) capabilities utilizing high-level manufacturing technologies, recent government legal reforms and industry promotion measures have transformed it from a mere manufacturing base into a critical gateway for Asian market strategies, including international partnerships, clinical trials, and market entry.

 

Overview of the Partnership

MetaTech AP was founded in 1998 as an electronic component distributor and later entered the medical field, including regenerative medicine.  The company has accumulated manufacturing data from its past experiences in a database and is collaborating with academic research institutions to develop AI algorithms.  By introducing the brain of smart manufacturing into cell production, the company aims to overcome challenges such as scaling production and quality control, making cell therapy more accessible.  In 2021, MetaTech AP established Locus Cell, a joint venture with leading companies for the manufacture and sale of cells for regenerative medicine.

Locus Cell, a CDMO (Contract Development and Manufacturing Organization) for regenerative medicine, is currently pursuing clinical manufacturing process certification from the US FDA and aims to acquire PMDA (Japan’s Pharmaceutical and Medical Devices Agency) certification in the future.  By elevating manufacturing quality and regulatory compliance to the highest international standards, Locus Cell is reinforcing its business expansion into the Japanese and broader Asian markets.

This partnership is expected to accelerate the development of a secure, reliable, and high-quality manufacturing system for MetaTech AP and Locus Cell in the regenerative medicine industry by integrating CM Plus’s expertise in production facility construction and regulatory compliance.

Furthermore, the companies plan to establish a GMP AI ecosystem spanning Japan and Taiwan using various digital technologies, including MetaTech AP’s “Neo-Katana”, and CM Plus’s “pharmo.AI” AI solution and “CORRESSA”* project collaboration platform.

Mr. Tsai Ming-Yaw, Deputy Representative of the Taiwan Representative Office, who attended the signing ceremony, expressed his expectations: “In a rapidly changing global industrial environment, smart manufacturing is key to enhancing competitiveness and innovation.  This collaboration brings together the expertise of both parties in technology development, process optimization, and digital transformation.  I am confident that it will generate strong synergies in areas like smart factories, automated production, and AI applications, bringing new vitality to the industry.”

 

* About “Neo-Katana”
Neo-Katana is a next-generation digital solution designed to streamline GMP documentation and compliance processes.  By integrating AI-assisted authoring and automated version control, the system helps biopharma manufacturers reduce human error, enhance regulatory alignment, and accelerate document approval cycles.

 

Service

• Regenerative Medicine Consulting